ArticleJAMIA open2026
Assessment of the adequacy of the Fast Healthcare Interoperability Resources (FHIR) Genomics standard for the representation of somatic testing reports.
Article in JAMIA open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Enabling the unambiguous communication of cancer genetic testing results and the corresponding therapeutic implications of identified genetic variants is of major clinical importance. In this report, we assess the adequacy of the Health Level Seven Fast Healthcare Interoperability Resources (FHIR) Genomics Reporting Implementation Guide, version 3 (also known as "FHIR Genomics") for the structured communication of semantic objects typically appearing in real-world somatic testing reports. Materials and Methods: The GenomeX project team, part of the CodeX FHIR Accelerator, performed the following assessment: (1) gather a convenience sample of public somatic reports; (2) create a representative somatic report that includes a wide range of observations taken from the sample reports; and (3) structure the representative somatic report using the FHIR Genomics standard. Results: Attempted encodings were categorized into 1 of the 4 buckets: (1) full encoding possible (eg, DNA variants); (2) full encoding with potential variability (eg, therapeutic implications); (3) partial encoding (eg, genomic study details); and (4) not encoded (ie, FHIR Genomics has no explicit or acceptable semantic target, such as for coarsely granular pertinent negatives). In our sample somatic report, 47 semantic objects were noted, of which 87% had either full encoding or full encoding with potential variability. Conclusion: While dynamic real-world requirements, as exemplified by cancer genomics, often arise more rapidly than can be standardized, we conclude that the FHIR Genomics version 3 standard is sufficiently robust for the communication of current actionable somatic testing results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.